AU2014302694B2 - Use of NK-1 receptor antagonist serlopitant in pruritus - Google Patents

Use of NK-1 receptor antagonist serlopitant in pruritus Download PDF

Info

Publication number
AU2014302694B2
AU2014302694B2 AU2014302694A AU2014302694A AU2014302694B2 AU 2014302694 B2 AU2014302694 B2 AU 2014302694B2 AU 2014302694 A AU2014302694 A AU 2014302694A AU 2014302694 A AU2014302694 A AU 2014302694A AU 2014302694 B2 AU2014302694 B2 AU 2014302694B2
Authority
AU
Australia
Prior art keywords
serlopitant
pharmaceutically acceptable
pruritus
polymorph
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014302694A
Other languages
English (en)
Other versions
AU2014302694A1 (en
Inventor
James W. Larrick
Andrew J. Perlman
Edward F. Schnipper
Xiaoming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyne Therapeutics Inc
Original Assignee
Menlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/925,509 external-priority patent/US8906951B1/en
Application filed by Menlo Therapeutics Inc filed Critical Menlo Therapeutics Inc
Publication of AU2014302694A1 publication Critical patent/AU2014302694A1/en
Assigned to MENLO THERAPEUTICS INC. reassignment MENLO THERAPEUTICS INC. Amend patent request/document other than specification (104) Assignors: Tigercat Pharma, Inc.
Application granted granted Critical
Publication of AU2014302694B2 publication Critical patent/AU2014302694B2/en
Priority to AU2020200259A priority Critical patent/AU2020200259A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014302694A 2013-06-24 2014-06-24 Use of NK-1 receptor antagonist serlopitant in pruritus Ceased AU2014302694B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020200259A AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361838784P 2013-06-24 2013-06-24
US13/925,509 US8906951B1 (en) 2013-06-24 2013-06-24 Use of NK-1 receptor antagonists in pruritus
US61/838,784 2013-06-24
US13/925,509 2013-06-24
PCT/US2014/043811 WO2014209962A1 (en) 2013-06-24 2014-06-24 Use of nk-1 receptor antagonist serlopitant in pruritus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200259A Division AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Publications (2)

Publication Number Publication Date
AU2014302694A1 AU2014302694A1 (en) 2016-01-07
AU2014302694B2 true AU2014302694B2 (en) 2019-10-17

Family

ID=51230173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014302694A Ceased AU2014302694B2 (en) 2013-06-24 2014-06-24 Use of NK-1 receptor antagonist serlopitant in pruritus
AU2020200259A Abandoned AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020200259A Abandoned AU2020200259A1 (en) 2013-06-24 2020-01-14 Use of NK-1 receptor antagonist serlopitant in pruritus

Country Status (13)

Country Link
EP (1) EP3013336A1 (ko)
JP (2) JP2016523260A (ko)
KR (1) KR20160023692A (ko)
CN (1) CN105473138A (ko)
AU (2) AU2014302694B2 (ko)
BR (1) BR112015031724A2 (ko)
CA (1) CA2915474A1 (ko)
HK (1) HK1223820A1 (ko)
IL (1) IL243189A0 (ko)
MX (2) MX366728B (ko)
PH (2) PH12015502777A1 (ko)
RU (1) RU2666219C2 (ko)
WO (1) WO2014209962A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
JP6741655B2 (ja) 2014-09-19 2020-08-19 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アプレピタントのエマルジョン製剤
MX2017011279A (es) 2015-03-04 2018-01-25 Vanda Pharmaceuticals Inc Metodo de tratamiento con tradipitant.
CN108883058A (zh) * 2016-02-01 2018-11-23 赫伦治疗有限公司 含有nk-1受体拮抗剂的乳剂
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
JP2019519592A (ja) * 2016-06-29 2019-07-11 メンロ セラピューティクス インコーポレイテッド 様々な掻痒状態を処置するためのニューロキニン−１アンタゴニストの使用
US11549147B2 (en) * 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
US11426408B2 (en) * 2017-11-01 2022-08-30 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
EP3746086A4 (en) * 2018-01-31 2021-10-20 TWI Biotechnology, Inc. TOPICAL FORMULATIONS INCLUDING TOFACITINIB
CN115015440A (zh) * 2022-07-08 2022-09-06 江苏杜瑞制药有限公司 一种生物样品中纳呋拉啡的检测方法
CN117503699A (zh) * 2023-12-08 2024-02-06 斯坦德医药研发(江苏)有限公司 阿瑞匹坦口服液制剂及制剂制造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100565A1 (en) 2001-09-21 2003-05-29 Boehringer Ingelheim International Gmbh Method for the treatment or prevention of atopic dermatitis
AR047439A1 (es) 2004-01-27 2006-01-18 Merck & Co Inc Antagonistas del receptor hidroisoindolina taquiquinina
CN100582093C (zh) * 2004-01-27 2010-01-20 默克公司 氢异二氢吲哚速激肽受体拮抗剂
DE602006020450D1 (de) 2005-07-11 2011-04-14 Merck Sharp & Dohme Ykinin-rezeptorantagonisten
AU2006302562A1 (en) 2005-10-04 2007-04-19 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
WO2007146224A2 (en) 2006-06-12 2007-12-21 Merck & Co., Inc. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2089019A4 (en) 2006-11-02 2011-05-04 Merck Sharp & Dohme POLYMORPHS OF AN ANTAGONIST OF TACHYKININ HYDRO-ISO-INDOLIC RECEPTORS
US20100113469A1 (en) 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
RU2370265C1 (ru) * 2008-03-04 2009-10-20 Лев Давидович Раснецов Гель, обладающий противовоспалительным и противоаллергическим действием

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A2 (en) * 2006-09-06 2008-03-13 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide

Also Published As

Publication number Publication date
JP2019142960A (ja) 2019-08-29
IL243189A0 (en) 2016-02-29
MX366728B (es) 2019-07-22
RU2666219C2 (ru) 2018-09-06
KR20160023692A (ko) 2016-03-03
RU2015154037A (ru) 2017-07-28
HK1223820A1 (zh) 2017-08-11
AU2014302694A1 (en) 2016-01-07
MX2015017763A (es) 2016-06-21
AU2020200259A1 (en) 2020-02-06
PH12020500255A1 (en) 2021-02-22
CA2915474A1 (en) 2014-12-31
WO2014209962A1 (en) 2014-12-31
CN105473138A (zh) 2016-04-06
EP3013336A1 (en) 2016-05-04
JP2016523260A (ja) 2016-08-08
BR112015031724A2 (pt) 2017-07-25
MX2019008643A (es) 2019-09-10
PH12015502777A1 (en) 2016-03-21

Similar Documents

Publication Publication Date Title
US10702499B2 (en) Use of NK-1 receptor antagonists in pruritus
AU2014302694B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US11026920B2 (en) Use of NK-1 receptor antagonist serlopitant in pruritus
US20190216779A1 (en) Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
MX2015004162A (es) Usos novedosos.
WO2020023898A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
US20200121695A1 (en) Compositions and methods for treating itch, skin inflammation, and pruritus

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired